This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

31 Jan 2011

Study Boosts Roche Bid for Tarceva Use

Roche, the world's largest maker of cancer drugs, said its study results gave the company a boost as Tarceva allows patients to live longer without their disease getting worse.

Switzerland-based Roche has some new findings to bolster broader use of its cancer treatment Tarceva. In a new study--stopped early because of the results--the drug kept cancer from progressing in patients newly diagnosed with EGFR-positive, non-small cell lung cancer. Roche said it will now ask U.S. FDA to approve Tarceva as an initial treatment in patients with this type of cancer.


"The Eurtac study demonstrates that testing for EGFR activating mutations can identify...candidates to receive Tarceva as their initial treatment for ad

Related News